miR-199b significantly inhibits both PI3K/Akt and ERK signaling activation in vitro and in vivo, suggesting that miR-199b exerts its anticancer function through the simultaneous inhibition of both Akt and ERK signaling in NSCLC. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.